Natera Inc known worldwide for its work in cell free DNA and precision medicine has announced the completion of its acquisition of Foresight Diagnostics. Foresight is a cancer diagnostics company with a CLIA registered lab and is well regarded for its highly sensitive molecular residual disease testing. The company uses circulating tumor DNA based MRD tests built on its patented PhasED Seq technology which focuses on phased variants. This approach has allowed Foresight to report impressive detection sensitivity with an LOD95 close to 0.3 parts per million and in some studies performance that reaches below 0.1 ppm.
Health Technology Insights: Kibow Biotech Launches Renadyl Advanced Multivitamin for Kidney Health
Foresight was created by a group of Stanford University scientists and physicians including Maximilian Diehn M D Ph D Ash Alizadeh M D Ph D and David Kurtz M D Ph D along with Jake Chabon Ph D who serves as both chief scientific officer and chief executive officer. Under their leadership the company has produced more than forty scientific papers and conference presentations and has collaborated with over thirty partners across biopharma and academic research.
Natera explained that the acquisition is designed to combine its established commercial reach and operational scale in personalized MRD testing with the specialized phased variant technology developed by Foresight. The company noted that the move builds on its existing intellectual property in tumor informed MRD approaches including work involving phased variants. Natera expects this combination to accelerate the integration of MRD testing in lymphoma and eventually in other solid tumor areas.
Health Technology Insights: Herantis Pharma Announces Successful Completion of Six-Month Glp Toxicology Study of Her-096
With the addition of Foresight technology Natera plans to enhance its Signatera platform by incorporating phased variants. This update is intended to improve performance across a range of solid tumor types. The upgraded version is already available to research partners in both academia and biopharma and Natera anticipates a full clinical release in 2026.
The acquisition also expands Natera leadership in lymphoma. Foresight has built strong momentum in research related to B cell lymphomas which account for more than seventy five thousand new cases each year in the United States. Earlier in the year data from Foresight helped support the inclusion of circulating tumor DNA MRD in the National Comprehensive Cancer Network Clinical Practice Guidelines for diffuse large B cell lymphoma. The company’s CLARITY MRD test is already being used in several prospective clinical trials that use MRD information to guide treatment decisions. Foresight CLARITY will now be part of Natera broader MRD portfolio and will continue to serve future clinical trials and translational research.
Both organizations will participate in the American Society of Hematology Annual Meeting beginning December 6 where they will present a combined total of fifteen abstracts that feature work on Signatera and PhasED Seq. Seven of these will be oral presentations highlighting the growing scientific weight behind the combined technologies and their potential to influence future standards in cancer monitoring.
Health Technology Insights: InteliChart Launches InteliSense to Power a New Era of Patient Engagement
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
